Goldline Pharmaceutical Ltd. IPO

Goldline Pharmaceutical 

• Goldline Pharmaceutical is coming out with an initial public offering (IPO) of 27,00,000 shares in a price band of Rs 41-43 per equity share. 
• The issue will open on May 12, 2026 and will close on May 14, 2026.
• The shares will be listed on SME Platform of BSE.
• The face value of the share is Rs 10 and is priced 4.1 times of its face value on the lower side and 4.3 times on the higher side.
• Book running lead manager to the issue is Cumulative Capital.
• Compliance Officer for the issue is Ruchi Sanket Modi.

Profile of the company

Goldline Pharmaceutical is engaged in the business of marketing pharmaceutical products under the brand name ‘Goldline’. Its product portfolio is organized into five distinct segments: Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness. The pharmaceutical products marketed under the ‘Goldline’ brand are not manufactured by the company. Instead, it enters into contractual arrangements with third-party manufacturers, who produce the products based on its market research, demand analysis, and specifications. These contractual arrangements ensure that all products meet the requisite quality standards and regulatory norms.

The products are marketed and sold exclusively under the ‘Goldline’ brand. Its customers primarily comprise distributors, who further supply to retailers and wholesalers, forming the main channel of distribution to the end-users. Presently, it maintains contractual arrangements with 15 manufacturers and 8 distributors, ensuring a stable supply chain and consistent market presence.

Under the third-party manufacturing model, the primary responsibility and product liability in respect of each formulation rests with the respective manufacturer. The manufacturer is solely responsible for ensuring that products are manufactured in compliance with the Drugs and Cosmetics Act, 1940 and the rules made thereunder, and that such products always conform to the specifications prescribed under the applicable pharmacopoeia standards. Notwithstanding the above, as a responsible organisation operating in the pharmaceutical sector, the company accords highest priority to addressing any quality-related concerns or complaints pertaining to products marketed under its brand.

Proceed is being used for:

• Repayment of all or a portion of certain outstanding borrowings availed by the company
• General corporate purposes

Industry overview

Indian pharmaceutical industry is known for its generic medicines and low-cost vaccines globally. Transformed over the years as a vibrant sector, presently Indian pharma ranks third in pharmaceutical production by volume. The Pharmaceutical industry in India is the third largest in the world in terms of volume and 14th largest in terms of value. The pharma sector currently contributes to around 1.72% of the country’s GDP. The Indian pharmaceuticals industry is expected to grow 9-11% in the financial year 2024.

In FY23, the Indian pharma market saw a year-on-year growth of nearly 5%, reaching $49.78 billion. During FY18 to FY23, the Indian pharmaceutical industry logged a compound annual growth rate (CAGR) of 6-8%, primarily driven by an 8% increase in exports and a 6% rise in the domestic market. Major Segments of the Pharmaceutical Industry are Generic drugs, OTC Medicines and API/Bulk Drugs, Vaccines, Contract Research & Manufacturing, Biosimilars & Biologics. Market size of India pharmaceuticals industry is expected to reach $65 billion by 2024, $130 billion by 2030 and $450 billion market by 2047. India is 3rd largest market for APIs globally, 8% share in the Global API Industry, 500+ different APIs are manufactured in India, and it contributes 57% of APIs to the prequalified list of the WHO. Pharmaceutical is one of the top ten attractive sectors for foreign investment in India. The pharmaceutical exports from India reach more than 200 nations around the world, including highly regulated markets of the USA, West Europe, Japan, and Australia.

The Government has put in place an investor-friendly Foreign Direct Investment (FDI) policy to promote investment in the sector. 100% foreign investment is allowed under automatic route in Medical Devices. In pharmaceuticals, up to 100% FDI in greenfield projects and up to 74% FDI in brownfield projects is allowed under the automatic route. Foreign investment beyond 74% in brownfield projects requires Government approval. After the abolition of the Foreign Investment Promotion Board (FIPB) in May 2017, the Department of Pharmaceuticals has been assigned the role to consider the foreign investment proposals under the Government approval route.

Pros and strengths

Asset-light business model and competitive products: The business model focuses on sourcing products of required quality through a manufacturer based on relationships with manufacturing partners. This allows for scaling operations without incurring capital expenditure on manufacturing facilities. The company operates on an asset-light business model, avoiding heavy investment in physical assets such as plants and machinery. This model supports capital efficiency, allows for expansion into new markets and distribution channels, and facilitates better cash flow management and lower risk.

Scalable business model: The business model is customer-centric and order-driven, requiring optimal utilization of resources, ensuring quality supply, and achieving economies of scale. Growth is supported by relationships with pharma manufacturers and the development of new markets and products by understanding customer needs and expanding the distribution network. The business model allows for scalability.

Wide and diverse range of product offerings: The company offers a range of products across Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, Goldline Wellness. Products are manufactured through contract manufacturing based on demand estimation and client requirements. The Company has the resources, experience, and network to introduce additional products.

Risks and concerns

Dependence on Goldline Pharma and Goldline Cardinal segments: The Company significantly depends on the Goldline Pharma and Goldline Cardinal segments for its revenue generation. The Goldline Pharma segment contributed 46.63%, 48.18%, 43.56%, and 51.53% to the Company’s revenue from operations during the nine months ended December 31, 2025, Fiscal 2025, Fiscal 2024, and Fiscal 2023, respectively, while the Goldline Cardinal segment contributed 26.46%, 24.64%, 28.36%, and 29.15%, respectively. Any reduction in demand for Goldline Pharma and Goldline Cardinal products could materially and adversely affect the company’s business, results of operations, and financial condition.

Dependence on limited geographies for revenue: It operates in limited geographies for a significant portion of its revenue. Its operations are based out of limited region like Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, Bihar, Chhattisgarh, Uttar Pradesh and Goa. The company derives a significant portion of its revenue from Maharashtra and Madhya Pradesh. Maharashtra contributed 44.36%, 47.54%, 50.50%, and 50.82% to the company’s total revenue as of December 31, 2025, March 31, 2025, March 31, 2024, and March 31, 2023, respectively, while Madhya Pradesh contributed 26.51%, 28.75%, 26.08%, and 22.02%, respectively. Its geographic concentration may have a have a material adverse effect on its business, results of operations and financial condition.

High working capital requirements: Its business requires significant amount of working capital and major portion of its working capital is utilized towards inventories and trade receivables. Its growing scale and expansion, if any, may result in increase in the quantum of current assets. Its inability to maintain sufficient cash flow, credit facility and other sources of funding, in a timely manner, or at all, to meet the requirement of working capital or pay out debts, could adversely affect its financial condition and result of its operations. Further, it has high outstanding amount due from its debtors which may result in a high risk in case of non-payment by these debtors. In case of any such defaults from its debtors, may affect its business operations and financials.

Outlook

Goldline Pharmaceutical is engaged in the business of marketing pharmaceutical products under the Goldline brand. Its products are divided into five categories: Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Valiente. Its primary customers are distributors, who are further categorized as retailers and wholesalers. These distributors serve as the key channel through which its products reach the end-users. On the concern side, it relies entirely on third-party contract manufacturers for the manufacturing of its pharmaceutical products, and any failure or inability of such manufacturers to meet quality, regulatory, delivery or capacity requirements could adversely affect its business, results of operations and financial condition. Further, its business largely depends on the performance of its marketing team. 

The company is coming out with a maiden IPO of 27,00,000 equity shares of face value of Rs 10 each. The issue has been offered in a price band of Rs 41-43 per equity share. The aggregate size of the offer is around Rs 11.07 crore to Rs 11.61 crore based on lower and upper price band respectively. On performance front, during Fiscal 2025, revenue from operations stood at Rs 2,805.57 lakh, compared to Rs 2,356.60 lakh in Fiscal 2024, representing a 19.05% jump. The Profit After Tax (PAT) for Fiscal 2025 reached Rs 283.22 lakh, marking an increase from Rs 180.40 lakh in Fiscal 2024, up by 57%.

Meanwhile, it considers efficient inventory management as key to the part of its business. Its inventory management processes include product allocation and store planning based on an assessment of sales potential and requirements. It has strict inventory management and monitoring systems, in order to manage an appropriate level of inventory for each of its products, to ensure sufficient supply. It plans its inventory procurement by forecasting demand for QoQ based on its targeted sales and inventory turnover and also based on its previous quarter’s demand analysis. It generally endeavors to maintain inventory levels in line with customer demand. It continuously looks for opportunities to optimize its supply chain network as well as warehouse processes to optimize its efficiency and productivity. It relies on third party agencies logistics vehicles to transport the products. Additionally, it has contracts with third-party agencies specializing in logistics and courier services, including to ensure smooth and timely transportation of its products.

Adon Agro Commodities

• Adon Agro Commodities is coming out with an initial public offering (IPO) of 62,90,000 shares in a price band of Rs 66-70 per equity share.
• The issue will open on June 29, 2026 and will close on July 01, 2026.
• The shares will be listed on SME Platform of BSE.
• The face value of the share is Rs 10 and is priced 6.60 times of its face value on the lower side and 7.00 times on the higher side.
• Book running lead manager to the issue is Galactico Corporate Services.
• Compliance officer for the issue is Snehal Gajanan Mhatre.

Profile of the company

Adon Agro Commodities operates in the agro-commodity trading and processing sector, primarily engaged in the sourcing, importing, processing, packing and distribution of dry fruits, nuts, seeds and berries. Its product portfolio includes, inter alia, almonds, walnuts, dates, pistachios, apricots, raisins and other allied products. It endeavours to maintain quality standards across its operations, with a focus on product quality, customer requirements and responsible business practices. It sources dry fruits, nuts, seeds and berries both domestically and internationally from countries including the United Arab Emirates, Afghanistan, Chile, the United States of America and Sri Lanka. The sourced products are sold in bulk to business to-business (B2B) customers and are also processed, packed and marketed under its proprietary brand ‘Hunger Nuts’ for sale to wholesale and retail customers under B2B and D2C segments.

Leveraging its established sourcing and procurement capabilities, it has gradually expanded its product range and developed an integrated business model encompassing procurement from India and overseas markets, processing, packing and sale of products. Sales are undertaken in bulk for B2B customers and through retail channels under the ‘Hunger Nuts’ brand. Its presence in the Agricultural Produce Market Committee (APMC), Navi Mumbai, and its engagement with intermediaries and select third-party distributors in various states in India, supports the distribution of both processed and unprocessed dry fruits across multiple product categories.

Its product offerings comprise various qualities of dry fruits such as almonds, cashews, walnuts, raisins and pistachios, sourced from multiple geographies. It has implemented internal quality control processes to ensure that products meet defined standards prior to sale. Its business strategy is focused on catering to the growing demand for nutritious food products and addressing the needs of lifestyle-conscious consumers. Its distribution channels include direct sales, wholesale and retail outlets, as well as digital platforms. In addition to its own website, its products are listed on leading e-commerce marketplaces and are also available through select large-format retail stores. Backed by the experience of its dynamic Promoters in the agro-produce industry, it seeks to further strengthen its market presence and expand its customer base.

Proceed is being used for:

• Funding incremental working capital requirements
• General corporate purpose

Industry overview

The Indian nuts and dry fruits market constitutes a segment of the broader Indian Food and Beverage (F&B) industry. The segment includes products consumed in raw, processed, or packaged forms and caters to household consumption as well as institutional, food processing, confectionery, bakery, and gifting applications. The market operates within an ecosystem influenced by agricultural availability, consumer consumption behaviour, retail channel development, and macroeconomic factors. The nuts and dry fruits industry in India is characterised by a combination of domestic agricultural production and imports, driven by agro-climatic diversity, crop-specific suitability, scale of cultivation, and processing capabilities. Domestic production is concentrated in select regions, while several categories-particularly tree nuts and premium dry fruits-remain structurally import-dependent due to climatic limitations and limited commercial cultivation.

The Indian nuts and dry fruits market, is estimated at around $25444 million in FY2025, is projected to reach $36055 million by FY2030, reflecting a CAGR of 7.22%, driven by shifts in dietary habits, premiumisation, rapid urbanisation, and the deepening penetration of e-commerce, quick-commerce, and modern retail platforms. Domestic consumption is expanding across both mass-market and premium categories. Groundnuts continue to dominate in volume terms due to their affordability, availability, and use across oil extraction, snacks, and traditional foods. In contrast, almonds, cashews, walnuts, and pistachios are increasingly viewed as premium, protein-rich, and health-forward products, accelerating demand among urban and health-conscious consumers. Dry fruits - especially raisins and dates - have gained traction in bakery, confectionery, breakfast cereals, trail mixes, nutritional supplements, and festive gifting, benefiting from growing interest in natural sweeteners, clean-label ingredients, and functional nutrition.

The future outlook for the Indian nuts and dry fruits industry remains strongly positive, supported by sustained structural demand, improving supply-chain integration, and continued formalisation. Rising disposable incomes, accelerated urban consumption, and the shift toward healthier snacking are expected to deepen penetration across both metropolitan and Tier II/III markets. Consumption will also rise as nuts, seeds, and berries become a regular component of packaged foods, bakery, confectionery, dairy alternatives, nutraceuticals, and ready-to-eat products, creating stable institutional demand. Supply-side dynamics are anticipated to improve with increased orchard productivity, expanded post-harvest infrastructure, scientific grading and sorting, and better cold-chain logistics. Government-backed programmes for horticulture development, GI tagging, export facilitation, and quality certification are expected to support long-term capacity enhancement. At the same time, India’s strategic positioning as a major processing and value-addition hub-supported by investments in roasting, flavouring, packaging, and private-label manufacturing-will continue to attract organised players.

Pros and strengths

Global sourcing network: The company has established trust-based relationships with suppliers across Asia, the Middle East, Chile and Australia, ensuring a consistent and reliable supply of high-quality dry fruits to meet growing market demands. 

Product innovation: The company places strong emphasis on continuous focus on research and development to innovate and diversify its product offerings. By staying ahead of market trends and consumer preferences, it strives to introduce new, high-quality products. 

Efficient distribution & logistics: Strategic logistics partnerships enhance the efficiency and reliability of product delivery. Such collaborations also allow businesses to scale operations and optimize supply chain costs.

Risks and concerns

Import tariff and duty fluctuations: It faces a financial risk related to customs duties and import tariffs on dry fruits sourced from international markets. If these duties unexpectedly increase, it could hurt the company's profitability and cash flow. Since customs duties and tariffs are recurring costs associated with its import-based business model, any unplanned rise in these charges could strain the company's financial resources, making it more difficult to maintain healthy profit margins or cover operational costs. This risk underscores the importance of monitoring and forecasting tariff expenses effectively.

Dependence on limited supplier for procurement of raw material: A substantial portion of the company’s purchases has been dependent upon a few suppliers. Its inability to obtain raw material in a timely manner, in sufficient quantities could adversely affect its operations, financial condition and/ or profitability. It depends on a number of suppliers, for procurement of raw materials required for processing of its products. For the stub period ended January 31, 2026 the top ten suppliers accounted for 50.21%, for the FY ended March 31, 2025 the company had only 5 suppliers they accounted for 100%, for the FY ended March 31, 2024 the company had only 4 suppliers and they accounted for 100% and for the FY ended March 31, 2023, the company had only 9 suppliers and they accounted for 100% of its total purchases respectively. It has not entered into long term contracts with its suppliers and prices for raw materials are normally based on the quotes it receives from various suppliers/brokers. Inadequate and unavailability/ substandard quality of the raw materials used in the manufacture of its products, could have a material adverse effect its business.

Risk of currency fluctuations: The company engages in import of dry fruits, which must comply with the rules and regulations set forth under FEMA. Its imports, expose it to currency fluctuation risks, which could directly impact its financial results. If it fails to adhere to the required timelines or are unable to manage currency fluctuation risks effectively, it could negatively affect its business, financial performance, and cash flows.

Outlook

Adon Agro Commodities operates in the agro-commodity processing and trading sector, primarily engaged in the sourcing, importing, exporting, processing, packing and distribution of dry fruits, nuts, seeds and berries. The sourced products are sold in bulk to business-to-business (B2B) customers and are also processed, packed and marketed under its proprietary brand ‘Hunger Nuts’ for sale to wholesale and retail customers. It has a rigorous quality control processes and advanced testing facilities maintain international standards. On the concern side, it is engaged in importing dry fruits and lacks backward integration into agricultural production or processing at the source. It is dependent on third-party suppliers and traders in source countries as well as in India for procurement, which limits its control over quality, availability, pricing, and supply chain of raw materials.

The company is coming out with a maiden IPO of 62,90,000 equity shares of face value of Rs 10 each. The issue has been offered in a price band of Rs 66-70 per equity share. The aggregate size of the offer is around Rs 41.51 crore to Rs 44.03 crore based on lower and upper price band respectively. On performance front, the revenue from operations of the company for FY24-25 was Rs 10,303.55 lakh as against Rs 7,256.71 lakh for FY23-24, an increase of 41.99%. Profit after tax for the FY24-25 was at Rs 722.05 lakh against profit after tax of Rs 179.10 lakh in FY23-24, an increase of 303.15%.

The company aims to enhance customer satisfaction by ensuring prompt and reliable deliveries, while also expanding its market reach by entering new regions. Additionally, it focuses on driving business growth through a streamlined and efficient supply chain, enabling better service and wider distribution. Going forward, it plans to explore opportunities in the retail sector by introducing products such as chips, dips and sauces. These additions will be considered based on the operational feasibility, profitability and stability of the market, aligning with its broader strategy to diversify its product portfolio and respond to evolving consumer preferences.